Alecensa (alectinib)

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

ALK inhibitor

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Neuroendocrine Tumor	ALK positive	Neuroendocrine Tumor	alectinib Sensitive: C1 - Off-label alectinib Sensitive : C1	alectinib Sensitive: C1 - Off-label alectinib Sensitive : C1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	atezolizumab + alectinib Sensitive: C2 – Inclusion Criteria atezolizumab + alectinib Sensitive : C2	atezolizumab + alectinib Sensitive: C2 – Inclusion Criteria atezolizumab + alectinib Sensitive : C2
ALK rearrangement	Solid Tumor	ALK rearrangement	Solid Tumor	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2
ALK fusion	Lung Adenocarcinoma	ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK-HIP1 fusion	Non Small Cell Lung Cancer	ALK-HIP1 fusion	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK G1269A	Non Small Cell Lung Cancer	ALK G1269A	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK R1231W	Non Small Cell Lung Cancer	ALK R1231W	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK I1171S	Non Small Cell Lung Cancer	ALK I1171S	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK L1196M	Non Small Cell Lung Cancer	ALK L1196M	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK G1128A	Non Small Cell Lung Cancer	ALK G1128A	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK I1171N	Non Small Cell Lung Cancer	ALK I1171N	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK F1174V	Non Small Cell Lung Cancer	ALK F1174V	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK S1157F	Non Small Cell Lung Cancer	ALK S1157F	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK C1156F	Non Small Cell Lung Cancer	ALK C1156F	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
KIF5B-RET fusion	Lung Cancer	KIF5B-RET fusion	Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib + alectinib Sensitive: C3 – Early Trials crizotinib + alectinib Sensitive : C3	crizotinib + alectinib Sensitive: C3 – Early Trials crizotinib + alectinib Sensitive : C3
STRN-ALK fusion + MET amplification	Non Small Cell Lung Cancer	STRN-ALK fusion + MET amplification	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
LMO7-ALK fusion	Non Small Cell Lung Cancer	LMO7-ALK fusion	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	crizotinib + alectinib Sensitive: C3 – Early Trials crizotinib + alectinib Sensitive : C3	crizotinib + alectinib Sensitive: C3 – Early Trials crizotinib + alectinib Sensitive : C3

Alecensa (alectinib)

Associations
(104)

Associations
(104)

Alecensa (alectinib)

Associations(104)

Associations(104)

Associations
(104)

Associations
(104)